Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Pearlstein
Robert
R
Department of Chemistry, Investigative PK, and Drug Safety Evaluation, Aventis Pharmaceuticals, Inc. Bridgewater, New Jersey 08807-0800, USA.
Vaz
Roy
R
Rampe
David
D
D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; D064420:Drug-Related Side Effects and Adverse Reactions; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced; D008958:Models, Molecular; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D015221:Potassium Channels / Q000737:chemistry / Q000187:drug effects*; D024642:Potassium Channels, Voltage-Gated; D013329:Structure-Activity Relationship; D016171:Torsades de Pointes / Q000139:chemically induced; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG
D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; C000606913:KCNH2 protein, human; C092509:KCNH6 protein, human; D004364:Pharmaceutical Preparations; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG